Reference number : 172-2021-2022-Q1-971037, amendment number : 1, agreement type : G, recipient legal name : Kyoto University, recipient country : JP, recipient province : nan, recipient city : Kyoto-shi, recipient postal code : nan, program name english : Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives, program name french : Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D, program purpose english : Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas., program purpose french : Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires., agreement title english : Automation of precision gene editing platform to accelerate engineering of human induced pluripotent stem cells, agreement title french : Automatisation de la plateforme d’édition génomique de précision en vue d’un modelage plus rapide des cellules souches pluripotentes induites humaines, agreement number : 991892, agreement value : 750000.0, agreement start date : 2021-04-01, agreement end date : 2025-03-31, description english : Exploiting genome editing technology to engineer enhanced and novel therapeutic attributes into clinically relevant cell types represents a disruptive modality to circumvent current challenges in cell- and gene-based therapies. The goal of this Project is to establish genome engineering tools amenable to automated and high throughput platforms that facilitate the engineering of therapeutic attributes into human induced pluripotent stem cells (iPSCs). Once established, these tools will be foundational to accelerating the innovation and discovery cycles of engineered cell-based therapies with increased safety, affordability and accessibility in the space of regenerative medicine and immunotherapy., description french : Automatisation de la plateforme d’édition génomique de précision en vue d’un modelage plus rapide des cellules souches pluripotentes induites humaines, expected results english : In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems., expected results french : À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides., additional information english : This agreement has been amended 1 time(s). The end date of this agreement has been modified by 365 days., additional information french : Cet accord a été modifié 1 fois.  La date de fin du présent accord a été changé de 365 jours., owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada